High IF Citations

【Cited FineTest Elisa Kit】 Current Research on Cancer Immunotherapy and Nanoparticle Drug Delivery

FineTest Elisa kit contributes to the research on cancer immunotherapy and nanoparticle drug delivery. The immunoassay is designed to measure OVA sIgG concentration in serum.

Publication Details
Article Title: Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors
Journal Title: Acta Pharmaceutica Sinica B
DOI: 10.1016/j.apsb.2022.04.018
IF: 11.614

Abstract: Utilization of the intestinal lymphatic pathway will allow extraordinary gains in lymph and tumors cascade-targeted delivery of oral drugs and awakening the innate/adaptive immunity of the body and the lesion microenvironment, in addition to improving oral bioavailability relative to other means of delivery of oral drugs. Here, inspired by the specific invasion route of intestinal microorganisms, we pioneered an immune-awakening Saccharomyces-inspired mesoporous silicon nanoparticle (yMSN) for the ingenious cascade-targeted delivery of therapeutic cancer vaccines and antitumor drugs to lymph and tumors via the intestinal lymphatic pathway. Encouragingly, yMSN high-loaded tumor-specific antigens (OVA, 11.9%) and anti-tumor drugs (Len, 28.6%) with high stability, namely Len/OVA/yMSN, efficiently co-delivered OVA and Len to their desired target sites. Moreover, yMSN concomitantly awakened the innate antitumor immunity of dendritic cells and macrophages, strengthening vaccine-induced adaptive immune responses and reversing macrophage-associated immunosuppression in the tumor microenvironment. Surprisingly, Len/OVA/yMSN treatment resulted in excellent synergistic antitumor efficacy and long-term antitumor memory in OVA-Hepa1-6-bearing mice. This high-performance nanocarrier provides a novel approach for lesion-targeting delivery of oral drugs accompanied with awakening of the innate/adaptive immunity of the lesion environment, and also represents a novel path for the oral delivery of diverse therapeutic agents targeting other lymph-mediated diseases.

Keywords: Oral delivery, Saccharomyces-inspired, Immune-awakening nanoparticles, Intestinal lymphatic pathway, Vaccine delivery, Cascade-targeted delivery, Awakening the innate/adaptive immunity, Co-delivery

Immunoassay

FineTest Product Sample Detection Target Species
Mouse OVA sIgG(Ovalbumin Specific IgG) ELISA Kit (EM1255) serum OVA sIgG mouse

Validated Image

nanoparticle vaccine delivery

Figure Source: Acta Pharmaceutica Sinica B, doi: 10.1016/j.apsb.2022.04.018.

Figure 7.   Adaptive immunomodulatory efficacy of the Len/OVA/yMSN on DCs: (E) OVA-specific IgG antibody after 7, 21 and 28 days after vaccinations of the C57BL/6 mice with orally administrated (p.o.) of OVA solution, Len/OVA/MSN, Len/OVA/yMSN, and subcutaneous injection (s.c.) of OVA solution, respectively (n = 3). All of the data are presented as the mean ± SD. ∗∗P < 0.01; ∗∗∗P < 0.001.